Methods for determining epidermal growth factor receptor-amplification status for clinical trials

Lesen Sie diesen Artikel auf Deutsch.

Takeaway

  • Cutoff to determine epidermal growth factor receptor (EGFR) gene amplification by fluorescence in situ hybridization (FISH) should be increased to >50% of EGFR-amplified (EGFR-amp) cells, and EGFR expression by real-time quantitative polymerase chain reaction (RT-qPCR) can act as a surrogate marker for EGFR-amp.

Why this matters

  • GBM is the most common and aggressive primary brain tumor, and EGFR is mutated in approximately half of all GBM tumors, leading to amplification of the gene.

  • Precision medicine specifically targeting EGFR-positive GBMs is under investigation, but there was no standard available for the method or cutoffs used to determine the amplification status of EGFR prior to this publication.

  • This publication should aid in the selection of patients into future precision medicine trials.

Mochten Sie mehr lesen?

Möchten Sie mehr lesen?

Loggen Sie sich ein oder registrieren Sie sich, um Zugang zu allen Inhalten von Neurodiem zu erhalten.

Sie haben bereits einen Account? Einloggen

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.